Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Mol Neurodegener ; 16(1): 5, 2021 01 31.
Article in English | MEDLINE | ID: mdl-33517893

ABSTRACT

BACKGROUND: Genome-wide association studies have established clusterin (CLU) as a genetic modifier for late-onset Alzheimer's disease (AD). Both protective and risk alleles have been identified which may be associated with its expression levels. However, the physiological function of clusterin in the central nervous system remains largely unknown. METHODS: We examined Clu expression in mouse brains by immunohistochemistry and high-resolution imaging. We performed electrophysiological recordings and morphological analysis of dendritic spines in wild-type and Clu knockout mice. We tested synaptic function of astrocytic Clu using neuron-glia co-cultures and by AAV-mediated astroglial Clu expression in vivo. Finally, we investigated the role of astrocytic Clu on synaptic properties and amyloid pathology in 5xFAD transgenic mouse model of AD. RESULTS: We show that astrocyte secreted Clu co-localizes with presynaptic puncta of excitatory neurons. Loss of Clu led to impaired presynaptic function and reduced spine density in vivo. Neurons co-cultured with Clu-overexpressing astrocytes or treated with conditioned media from HEK293 cells transfected with Clu displayed enhanced excitatory neurotransmission. AAV-mediated astroglial Clu expression promoted excitatory neurotransmission in wild-type mice and rescued synaptic deficits in Clu knockout mice. Overexpression of Clu in the astrocytes of 5xFAD mice led to reduced Aß pathology and fully rescued the synaptic deficits. CONCLUSION: We identify Clu as an astrocyte-derived synaptogenic and anti-amyloid factor; the combination of these activities may influence the progression of late-onset AD.


Subject(s)
Alzheimer Disease/metabolism , Astrocytes/metabolism , Clusterin/metabolism , Neurons/metabolism , Synaptic Transmission/physiology , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/metabolism , Animals , Clusterin/genetics , Disease Models, Animal , Genome-Wide Association Study , Humans , Mice, Transgenic , Neuropathology/methods , Synaptic Transmission/genetics
2.
Neuron ; 100(6): 1337-1353.e5, 2018 12 19.
Article in English | MEDLINE | ID: mdl-30415998

ABSTRACT

Strong evidence implicates the complement pathway as an important contributor to amyloid pathology in Alzheimer's disease (AD); however, the role of complement in tau modulation remains unclear. Here we show that the expression of C3 and C3a receptor (C3aR1) are positively correlated with cognitive decline and Braak staging in human AD brains. Deletion of C3ar1 in PS19 mice results in the rescue of tau pathology and attenuation of neuroinflammation, synaptic deficits, and neurodegeneration. Through RNA sequencing and cell-type-specific transcriptomic analysis, we identify a C3aR-dependent transcription factor network that regulates a reactive glial switch whose inactivation ameliorates disease-associated microglia and neurotoxic astrocyte signatures. Strikingly, this C3aR network includes multiple genes linked to late-onset AD. Mechanistically, we identify STAT3 as a direct target of C3-C3aR signaling that functionally mediates tau pathogenesis. All together our findings demonstrate a crucial role for activation of the C3-C3aR network in mediating neuroinflammation and tau pathology.


Subject(s)
Alzheimer Disease/metabolism , Brain/pathology , Complement C3a/metabolism , Cytokines/metabolism , Receptors, Complement/metabolism , Signal Transduction/physiology , Adult , Aged , Aged, 80 and over , Alzheimer Disease/complications , Alzheimer Disease/pathology , Animals , Brain/physiopathology , Calcium-Binding Proteins , Cognition Disorders/etiology , Complement C3a/genetics , DNA-Binding Proteins/metabolism , Disease Models, Animal , Evoked Potentials/physiology , Female , Gene Regulatory Networks/physiology , Humans , Male , Mice , Mice, Transgenic , Microfilament Proteins , Middle Aged , Receptors, Complement/genetics , Signal Transduction/drug effects , Tauopathies/complications , Up-Regulation/physiology , tau Proteins/genetics , tau Proteins/metabolism
3.
JCI Insight ; 3(13)2018 07 12.
Article in English | MEDLINE | ID: mdl-29997299

ABSTRACT

Nonneuronal cell types in the CNS are increasingly implicated as critical players in brain health and disease. While gene expression profiling of bulk brain tissue is routinely used to examine alterations in the brain under various conditions, it does not capture changes that occur within single cell types or allow interrogation of crosstalk among cell types. To this end, we have developed a concurrent brain cell type acquisition (CoBrA) methodology, enabling the isolation and profiling of microglia, astrocytes, endothelia, and oligodendrocytes from a single adult mouse forebrain. By identifying and validating anti-ACSA-2 and anti-CD49a antibodies as cell surface markers for astrocytes and vascular endothelial cells, respectively, and using established antibodies to isolate microglia and oligodendrocytes, we document that these 4 major cell types are isolated with high purity and RNA quality. We validated our procedure by performing acute peripheral LPS challenge, while highlighting the underappreciated changes occurring in astrocytes and vascular endothelia in addition to microglia. Furthermore, we assessed cell type-specific gene expression changes in response to amyloid pathology in a mouse model of Alzheimer's disease. Our CoBrA methodology can be readily implemented to interrogate multiple CNS cell types in any mouse model at any age.


Subject(s)
Alzheimer Disease/pathology , Brain/pathology , Inflammation/pathology , Alzheimer Disease/genetics , Animals , Astrocytes/metabolism , Astrocytes/pathology , Brain/metabolism , Disease Models, Animal , Endothelial Cells/metabolism , Endothelial Cells/pathology , Female , Gene Expression , Gene Expression Profiling , Inflammation/genetics , Integrin alpha1 , Male , Membrane Proteins , Mice , Mice, Inbred C57BL , Microglia/metabolism , Microglia/pathology , Oligodendroglia/metabolism , Oligodendroglia/pathology
4.
Nucleic Acids Res ; 38(12): 3963-74, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20194111

ABSTRACT

Numerous human pathologies result from unrepaired oxidative DNA damage. Base excision repair (BER) is responsible for the repair of oxidative DNA damage that occurs in both nuclei and mitochondria. Despite the importance of BER in maintaining genomic stability, knowledge concerning the regulation of this evolutionarily conserved repair pathway is almost nonexistent. The Saccharomyces cerevisiae BER protein, Ntg1, relocalizes to organelles containing elevated oxidative DNA damage, indicating a novel mechanism of regulation for BER. We propose that dynamic localization of BER proteins is modulated by constituents of stress response pathways. In an effort to mechanistically define these regulatory components, the elements necessary for nuclear and mitochondrial localization of Ntg1 were identified, including a bipartite classical nuclear localization signal, a mitochondrial matrix targeting sequence and the classical nuclear protein import machinery. Our results define a major regulatory system for BER which when compromised, confers a mutator phenotype and sensitizes cells to the cytotoxic effects of DNA damage.


Subject(s)
Cell Nucleus/enzymology , DNA Damage , DNA Repair , DNA-(Apurinic or Apyrimidinic Site) Lyase/chemistry , Mitochondria/enzymology , Saccharomyces cerevisiae Proteins/chemistry , Active Transport, Cell Nucleus , Amino Acid Substitution , DNA-(Apurinic or Apyrimidinic Site) Lyase/analysis , DNA-(Apurinic or Apyrimidinic Site) Lyase/metabolism , Nuclear Localization Signals , Oxidative Stress , Protein Sorting Signals , Saccharomyces cerevisiae Proteins/analysis , Saccharomyces cerevisiae Proteins/metabolism
5.
Mol Biol Evol ; 24(12): 2716-22, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17884825

ABSTRACT

Our understanding of the origins of new metabolic functions is based upon anecdotal genetic and biochemical evidence. Some auxotrophies can be suppressed by overexpressing substrate-ambiguous enzymes (i.e., those that catalyze the same chemical transformation on different substrates). Other enzymes exhibit weak but detectable catalytic promiscuity in vitro (i.e., they catalyze different transformations on similar substrates). Cells adapt to novel environments through the evolution of these secondary activities, but neither their chemical natures nor their frequencies of occurrence have been characterized en bloc. Here, we systematically identified multifunctional genes within the Escherichia coli genome. We screened 104 single-gene knockout strains and discovered that many (20%) of these auxotrophs were rescued by the overexpression of at least one noncognate E. coli gene. The deleted gene and its suppressor were generally unrelated, suggesting that promiscuity is a product of contingency. This genome-wide survey demonstrates that multifunctional genes are common and illustrates the mechanistic diversity by which their products enhance metabolic robustness and evolvability.


Subject(s)
Biological Evolution , Escherichia coli/genetics , Escherichia coli/metabolism , Suppression, Genetic , Autotrophic Processes/genetics , Bacterial Proteins/chemistry , Catalysis , Directed Molecular Evolution , Escherichia coli/enzymology , Phosphates/metabolism , Structural Homology, Protein , Substrate Specificity , Transformation, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL